The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00732654 |
Recruitment Status
:
Completed
First Posted
: August 12, 2008
Results First Posted
: May 15, 2017
Last Update Posted
: May 15, 2017
|
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Milk Allergy | Drug: Milk Protein Extract Immunotherapy goal of 4mg/day Drug: Milk Protein Extract Immunotherapy goal of 7mg/day Drug: Milk Powder Immunotherapy goal dose 2000 mg/day Drug: Milk Powder Immunotherapy goal dose 1000mg/day | Phase 1 Phase 2 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 30 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | The Safety and Efficacy of Sublingual/Oral Immunotherapy for the Treatment of Milk Protein Allergy |
Study Start Date : | August 2008 |
Actual Primary Completion Date : | June 2010 |
Actual Study Completion Date : | June 2012 |

Arm | Intervention/treatment |
---|---|
Experimental: Sublingual Immunotherapy (SLIT)
These subjects will have a dose escalation of the milk protein extract given sublingually. After dose escalation, they will continue on the sublingual daily maintenance dose for approximately one year. Milk Protein Extract Immunotherapy : Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years. |
Drug: Milk Protein Extract Immunotherapy goal of 4mg/day
Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Drug: Milk Protein Extract Immunotherapy goal of 7mg/day
Sublingual extract daily in escalating doses to goal of 7mg/day for approximately 1 1/2 years.
|
Experimental: SLIT/ Oral Immunotherpay (OIT) B
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 1000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years. |
Drug: Milk Protein Extract Immunotherapy goal of 4mg/day
Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Drug: Milk Powder Immunotherapy goal dose 1000mg/day
Milk powder given orally in escalating doses with a goal of 1000mg/day for approximately 1 1/2 years.
|
Experimental: SLIT/ OIT A
These subjects will start with a dose escalation of the milk protein extract given sublingually, and then will switch to milk powder given orally and will undergo a dose escalation for a goal of 2000 mg. After dose escalation, they will continue on the oral daily maintenance dose for approximately one year. Milk Powder Immunotherapy : Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years. Milk Protein Extract Immunotherapy : Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks. |
Drug: Milk Protein Extract Immunotherapy goal of 4mg/day
Sublingual extract given daily in escalating doses with goal of 4 mg/day for approximately 20 weeks.
Drug: Milk Powder Immunotherapy goal dose 2000 mg/day
Milk powder given orally in escalating doses with a goal dose of 2000mg/day given for approximately 1 1/2 years.
|
- Change in CM-specific Immunogloblin E (IgE) [ Time Frame: Change from baseline to after therapy (up to 18 months) ]Cow's milk specific IgE was measured at baseline and after therapy (kUa/L)
- Change in CM-specific Immunoglobulin G4 (IgG4) [ Time Frame: Change from baseline to after therapy (up to 18 months) ]Cow's milk specific IgG4 was measured at baseline and after therapy (kUa/L)
- Change in End Point Skin Test [ Time Frame: Change from baseline to after therapy (up to 18 months) ]Allergen provoked skin test (mm)
- Oral Food Challenge Threshold (OFC) Threshold [ Time Frame: Change from baseline to after therapy (up to 18 months) ]mg CM protein

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 6 Years to 21 Years (Child, Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Are age 6 to 21 years
- Provide signed informed consent (by parent or legal guardian if the subject is a minor), and informed assent if applicable
- Have a history of symptomatic reactivity to cow's milk (i.e. Eczema, urticaria, upper or lower respiratory symptoms, GI disturbances, other rash or oral symptoms)
- Have a positive skin prick test (defined as wheal 3 mm ≥ negative control) and cow's milk- immunoglobulin E (IgE) > 0.35 kilo Immunoglobulin Units (kIU)/L
- Have a positive OFC to cow's milk at a cumulative dose of less than 184 milligrams of cow's milk intact protein (2,400 mg total milk protein).
- Are using appropriate birth control if subject is female and of child bearing age.
- Have self-injectable epinephrine (ie. EpiPen® or EpiPen Jr.®) available at home
Exclusion Criteria:
- Have a history of severe anaphylaxis defined as hypoxia (cyanosis or SpO2 ≤ 92% at any stage), hypotension, confusion, collapse, loss of consciousness; or incontinence
- Have a history of intubation related to asthma
- Tolerate more than 184 milligrams of intact cow's milk protein at initial OFC
- Are pregnant or lactating
- Have a viral Upper Respiratory Infection (URI) or gastroenteritis within 7 days of OFC (OFC needs to be rescheduled)
- Have pulmonary function tests <80% of predicted (FEV1) or clinical history consistent with more than moderate persistent asthma
- Are currently taking greater than medium dose inhaled corticosteroid (>400 mcg/day fluticasone or fluticasone equivalent if ≤ 12 years old or > 600 mcg/day if > 12 years old)
- Are unable to discontinue antihistamines for 5 days for long acting and 3 days for short acting prior to skin testing or food challenges
- Have used systemic corticosteroids within 4 weeks prior to baseline visit
- Are receiving omalizumab, beta-blocker, Angiotensin Converting Enzyome (ACE) inhibitor or tricyclic antidepressant therapy
- Have a chronic disease (other than asthma, atopic dermatitis or rhinitis) requiring therapy (e.g., heart disease, diabetes)
- Have participated in any interventional study for treatment of a food allergy in the past 12 months
- Have a severe reaction at initial DBPCFC, defined as either:
Life-threatening anaphylaxis, or Reaction requiring hospitalization

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00732654
United States, Maryland | |
Johns Hopkins Hospital | |
Baltimore, Maryland, United States, 21287 | |
United States, North Carolina | |
Duke University | |
Durham, North Carolina, United States, 27710 |
Principal Investigator: | Robert Wood, MD | Johns Hopkins University |
Additional Information:
Responsible Party: | Johns Hopkins University |
ClinicalTrials.gov Identifier: | NCT00732654 History of Changes |
Other Study ID Numbers: |
NA_00732654 |
First Posted: | August 12, 2008 Key Record Dates |
Results First Posted: | May 15, 2017 |
Last Update Posted: | May 15, 2017 |
Last Verified: | April 2017 |
Keywords provided by Johns Hopkins University:
Food Allergy Oral Immunotherapy Immunoglobulin E |
Additional relevant MeSH terms:
Hypersensitivity Milk Hypersensitivity Immune System Diseases Food Hypersensitivity Hypersensitivity, Immediate |